COCOA, Fla., Dec. 15, 2011 /PRNewswire/ -- GeNO LLC (www.genollc.com), a privately held, advanced development-stage technology company, today announced it has been awarded two new US patents. The Company now has a total of nine issued US patents for its proprietary Nitric Oxide generation and delivery technology.
GeNO's eighth patent (8,057,742) on NITROSYL (nitric oxide) for inhalation concerns the conversion of nitrogen dioxide (NO2) to nitric oxide (NO) using the GeNO cartridge technology to scavenge nitrogen dioxide that may have been formed, for example, in the gas lines, and converting it back into nitric oxide. The system could be used as an add-on to existing technology and would remove residual toxic nitrogen dioxide impurity from the system. Importantly, this new patent does not expire until January 2026.
The ninth patent (8,066,904) relates to the controlled generation of nitric oxide. This patent describes a controlled release matrix made up of a nitric oxide-releasing agent, nitric oxide precursors, and a polymer binder into a unitary structure for delivering nitric oxide to a patient. The potential applications could include either an oral formulation or a salve. This patent does not expire until November 2027.
"These patents not only build on our company's strong intellectual property but also address some important possibilities to improve patient treatment with nitric oxide," said GeNO LLC Founder and President David Fine. "Using our proprietary technology the company has developed several distinct nitric oxide delivery platforms."
NITROSYL could add valuable options for clinicians treating a range of serious pulmonary and cardiac diseases with inhaled nitric oxide. GeNO's plans for both in-hospital and ambulatory inhaled nitric oxide systems would help address the cost, complexity and lack of portability of current treatment regimens, and would potentially reach a much larger group of patients. At present, GeNO's delivery technologies are investigational and are not approved by regulatory authorities.
GeNO is currently performing two Phase 2 trials: one, as a Pilot Study in Pulmonary Arterial Hypertension (PAH) and a second dose-escalation trial for the Treatment of Pulmonary Hypertension in patients with PAH and Pulmonary Hypertension secondary to Idiopathic Pulmonary Fibrosis (PH-IPF). Additional study details can be found at http://clinicaltrials.gov/ -- ClinicalTrials.gov Identifiers NCT01092559 and NCT01265888.
ABOUT GENO LLC
GeNO LLC, founded in 2006, is a privately held, advanced development-stage technology company that is developing innovative nitric oxide (NO) generation and delivery platforms to enable the true potential of inhaled nitric oxide to be realized. The company is focused on applying the new technology to deliver inhaled nitric oxide to patients in a wide variety of settings, including ambulatory and in-home use for potential chronic treatment. GeNO's NITROSYL Systems will be regulated by the FDA as new drugs with their own NDAs. These systems have been designated as Combination Products by the FDA Office of Combination Products, with the Division of Cardiovascular and Renal Products designated as the lead reviewer for GeNO's initial INDs.
Carla Burigatto, 610-457-2178
Brian Heffron, 781-799-9568
SOURCE GeNO LLC